Pharmacokinetics - PK

Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, Hanieh Abedian Kalkhoran, Egbert F Smit, Willemijn S M E Theelen

Journal for ImmunoTherapy of Cancer Feb 2025, 13 (2) e010065; DOI: 10.1136/jitc-2024-010065
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le, Justin Call, Fatima Rangwala, Guanfang Wang, Bo Ma, Simon Metenou, Jade Huguet, Elliot Offman, Lini Pandite, Erika Hamilton

Journal for ImmunoTherapy of Cancer Jan 2025, 13 (1) e010565; DOI: 10.1136/jitc-2024-010565
Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurelien Marabelle, Laurence Albiges, Angelo Paci

Journal for ImmunoTherapy of Cancer Jan 2025, 13 (1) e010059; DOI: 10.1136/jitc-2024-010059
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Diwakar Davar, Benedito A Carneiro, Grace K Dy, Siddharth Sheth, Mitesh J Borad, Kevin J Harrington, Sandip P Patel, Evanthia Galanis, Adel Samson, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Eric Tu, Nicholas Durham, Kevin Laubscher, Fernanda Arnaldez, Dmitriy Zamarin

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (11) e009336; DOI: 10.1136/jitc-2024-009336
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
Aung Naing, Danny Khalil, Oliver Rosen, D Ross Camidge, Tom Lillie, Rui-Ru Ji, Andrea Stacey, Matthew Thomas, Lee Rosen

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e010016; DOI: 10.1136/jitc-2024-010016
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
Bixia Tang, Yu Chen, Yu Jiang, Meiyu Fang, Quanli Gao, Xiubao Ren, Li Yao, Gang Huang, Jing Chen, Xiaoshi Zhang, Rongqing Li, Shuai Zhao, Meijuan Gao, Ruixuan Luo, Meng Qi, Feng Li, Fei Zheng, Michael Lee, Xiaolu Tao, Rong Duan, Jun Guo, Zhihong Chi, Chuanliang Cui

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e009662; DOI: 10.1136/jitc-2024-009662
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurelien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, Francois-Xavier Danlos

Journal for ImmunoTherapy of Cancer May 2024, 12 (5) e008847; DOI: 10.1136/jitc-2024-008847

Log in using your username and password

Main menu

Log in using your username and password

You are here

Pharmacokinetics - PK